{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "import os\n",
    "import logging"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Ignoring wrong pointing object 61 0 (offset 0)\n",
      "Ignoring wrong pointing object 70 0 (offset 0)\n"
     ]
    }
   ],
   "source": [
    "directory = \"/home/ubuntu/Multi-Agent-LLM-System-with-LangGraph-RAG-and-LangChain/filtered_dataset_csv_pdfs\"\n",
    "pdf_contents = {}\n",
    "for filename in os.listdir(directory):\n",
    "    if filename.endswith(\".pdf\"):\n",
    "        file_path = os.path.join(directory, filename)\n",
    "        loader = PyPDFLoader(file_path)\n",
    "        pages = loader.load()\n",
    "        content = \"\\n\".join(page.page_content for page in pages)\n",
    "        pdf_contents[filename] = content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:root:Processing file: 10.1371_journal.pone.0076906.pdf\n",
      "INFO:root:Processing file: 10.1038_srep04576.pdf\n",
      "INFO:root:Processing file: 10.3892_or.2011.1482.pdf\n",
      "INFO:root:Processing file: 10.1038_sj.ejhg.5201002.pdf\n",
      "INFO:root:Processing file: 10.1186_1757-2215-6-82.pdf\n",
      "INFO:root:Processing file: 10.1038_sj.bjc.6603553.pdf\n",
      "INFO:root:Processing file: 10.1186_1471-2121-13-9.pdf\n",
      "INFO:root:Processing file: 10.1186_1471-2350-12-138.pdf\n",
      "INFO:root:Processing file: 10.1101_gr.134445.111.pdf\n",
      "INFO:root:Processing file: 10.3892_ijo.2013.1916.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0016182.pdf\n",
      "INFO:root:Processing file: 10.1186_1471-2407-12-627.pdf\n",
      "INFO:root:Processing file: 10.3389_fphys.2014.00139.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0064496.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0075907.pdf\n",
      "INFO:root:Processing file: 10.3389_fncel.2013.00168.pdf\n",
      "INFO:root:Processing file: 10.3892_ol.2012.996.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0048533.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0077722.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0054136.pdf\n",
      "INFO:root:Processing file: 10.4081_aiua.2015.2.121.pdf\n",
      "WARNING:pypdf._reader:Ignoring wrong pointing object 61 0 (offset 0)\n",
      "WARNING:pypdf._reader:Ignoring wrong pointing object 70 0 (offset 0)\n",
      "INFO:root:Processing file: 10.1038_cr.2008.309.pdf\n",
      "INFO:root:Processing file: 10.3892_etm.2011.217.pdf\n",
      "INFO:root:Processing file: 10.2147_TCRM.S14015.pdf\n",
      "INFO:root:Processing file: 10.1158_0008-5472.CAN-06-2731.pdf\n",
      "INFO:root:Processing file: 10.1101_gr.132159.111.pdf\n",
      "INFO:root:Processing file: 10.1158_0008-5472.CAN-08-1954.pdf\n",
      "INFO:root:Processing file: 10.7314_apjcp.2013.14.2.1057.pdf\n",
      "INFO:root:Processing file: 10.3389_fendo.2012.00085.pdf\n",
      "INFO:root:Processing file: 10.3389_fncel.2014.00468.pdf\n",
      "INFO:root:Processing file: 10.4062_biomolther.2013.037.pdf\n",
      "INFO:root:Processing file: 10.1371_journal.pone.0044964.pdf\n",
      "INFO:root:Processing file: 10.3892_mmr.2013.1572.pdf\n",
      "INFO:root:Processing file: 10.3892_ijo.2012.1357.pdf\n",
      "INFO:root:Processing file: 10.3892_or.2012.1625.pdf\n",
      "INFO:root:Processing file: 10.1158_1078-0432.CCR-13-2436.pdf\n",
      "INFO:root:Processing file: 10.1186_1475-2867-13-86.pdf\n",
      "INFO:root:Processing file: 10.3892_or.2012.1760.pdf\n",
      "INFO:root:Processing file: 10.1101_gr.140475.112.pdf\n",
      "INFO:root:Processing file: 10.1038_leu.2013.304.pdf\n",
      "INFO:root:Processing file: 10.1158_1078-0432.CCR-11-1548.pdf\n",
      "INFO:root:Processing file: 10.1158_1078-0432.CCR-13-1275.pdf\n",
      "INFO:root:Processing file: 10.1007_s00280-014-2654-y.pdf\n"
     ]
    }
   ],
   "source": [
    "logging.basicConfig(level=logging.INFO)\n",
    "logger = logging.getLogger()\n",
    "\n",
    "directory = \"/home/ubuntu/Multi-Agent-LLM-System-with-LangGraph-RAG-and-LangChain/filtered_dataset_csv_pdfs\"\n",
    "pdf_contents = {}\n",
    "\n",
    "for filename in os.listdir(directory):\n",
    "    if filename.endswith(\".pdf\"):\n",
    "        file_path = os.path.join(directory, filename)\n",
    "        logger.info(f\"Processing file: {filename}\")\n",
    "        loader = PyPDFLoader(file_path)\n",
    "        pages = loader.load()\n",
    "        # logger.info(f\"Successfully processed file: {filename}\")\n",
    "        content = \"\\n\".join(page.page_content for page in pages)\n",
    "        pdf_contents[filename] = content\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "WARNING:pypdf._reader:Ignoring wrong pointing object 61 0 (offset 0)\n",
      "WARNING:pypdf._reader:Ignoring wrong pointing object 70 0 (offset 0)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "9\n",
      "121 Archivio Italiano di Urologia e Andrologia 2015; 87, 2ORIGINALPAPER\n",
      "Efﬁcacy and safety of second-line agents for treatment \n",
      "of metastatic castration-resistant prostate cancer\n",
      "progressing after docetaxel. \n",
      "A systematic review and meta-analysis\n",
      "Gianpaolo Perletti1,2, Elena Monti1, Emanuela Marras1, Anne Cleves3, Vittorio Magri4, \n",
      "Alberto Trinchieri5, Paul S. Rennie6\n",
      "1 Biomedical Research Division, Dept. of Theoretical and Applied Sciences, Università degli Studi dell'Insubria, Busto Arsizio, Italy\n",
      "2 Department of Basic Medical Sciences, Ghent University, Ghent, Belgium;\n",
      "3 Cancer Research Wales Library, Cardiff University Velindre Hospital, Cardiff, UK;\n",
      "4 Urology Secondary Care Clinic, Istituti Clinici di Perfezionamento, Milano, Italy;\n",
      "5 Urology Unit, A. Manzoni Hospital, Lecco, Italy;\n",
      "6 Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.\n",
      "Objective: We performed a systematic\n",
      "review of the literature to assess the efﬁca-\n",
      "cy and the safety of second-line agents targeting metastatic\n",
      "castration-resistant prostate cancer (mCRPC) that has pro-\n",
      "gressed after docetaxel. Pooled-analysis was also performed,\n",
      "to assess the effectiveness of agents targeting the androgen\n",
      "axis via identical mechanisms of action (abiraterone acetate,\n",
      "orteronel).\n",
      "Materials and Methods: We included phase III randomized\n",
      "controlled trials that enrolled patients with mCRPC progress-\n",
      "ing during or after ﬁrst-line docetaxel treatment. Trials were\n",
      "identiﬁed by electronic database searching. The primary out-\n",
      "come of the review was overall survival. Secondary outcomes\n",
      "were radiographic progression-free survival (rPFS) and severe\n",
      "adverse effects (grade 3 or higher).\n",
      "Results: Ten articles met the inclusion criteria for the review.\n",
      "These articles reported the results of ﬁve clinical trials,\n",
      "enrolling in total 5047 patients. The experimental interven-\n",
      "tions tested in these studies were enzalutamide, ipilimumab,\n",
      "abiraterone acetate, orteronel and cabazitaxel. \n",
      "Compared to control cohorts (active drug-treated or placebo-\n",
      "treated), the signiﬁcant overall survival advantages achieved\n",
      "were 4.8 months for enzalutamide (hazard ratio for death vs.\n",
      "placebo: 0.63; 95% CI 0.53 to 0.75, P < 0.0001), 4.6 months\n",
      "for abiraterone (hazard ratio for death vs. placebo: 0.66, 95%\n",
      "CI 0.58 to 0.75, P < 0.0001) and 2.4 months for cabazitaxel\n",
      "(hazard ratio for death vs. mitoxantrone-prednisone: 0.70,\n",
      "95% CI 0.59 to 0.83, p < 0.0001). Pooled analysis of androgen\n",
      "synthesis inhibitors orteronel and abiraterone resulted in\n",
      " signiﬁcantly increased overall and progression-free survival\n",
      "for anti-androgen agents, compared to placebo (hazard ratio\n",
      "for death: 0.76, 95% CI 0.67 to 0.87, P < 0.0001; hazard ratio\n",
      "for radiographic progression: 0.7, 95% CI 0.63 to 0.77,\n",
      "P<0.00001). Androgen synthesis inhibitors induced signiﬁ-\n",
      "cant increases in risk ratios for adverse effects linked to ele-\n",
      "vated mineralocorticoid secretion, compared to placebo (risk\n",
      "ratio for hypokalemia: 5.75, 95% CI 2.08 to 15.90;\n",
      "P=0.0008; risk-ratio for hypertension: 2.29, 95% CI 1.02\n",
      "to5.17; P=0.05).\n",
      "Conclusions: In docetaxel-pretreated patients enzalutamide,\n",
      "abiraterone-prednisone and cabazitaxel-prednisone can\n",
      "improve overall survival of patients, compared to placebo orSummary\n",
      "No conﬂict of interest declared. INTRODUCTION\n",
      "Metastatic prostate cancer results from any combination\n",
      "of lymphatic, blood, or local spread, leading to various\n",
      "sorts of clinical presentations. The most common sites of\n",
      "metastasis are bone, lymph nodes and/or other visceral\n",
      "locations (1) At this stage of the disease, the first-line\n",
      "treatment is surgical or pharmacological androgen depri-\n",
      "vation, to achieve castrate testosterone levels of 50 ng/dL\n",
      "or lower (2). Inevitably, the disease undergoes transition\n",
      "to castration-resistant prostate cancer (CRPC) (2). \n",
      "In men with metastatic CRPC (mCRPC), docetaxel 75\n",
      "mg/m2every 3 weeks, combined with low-dose corticos-\n",
      "teroids, is the standard intervention (3, 4). However, in\n",
      "all patients the disease rapidly progresses to a docetaxel-\n",
      "refractory status, characterized by a time to progression\n",
      "of 3 months or less (5). Recently, new agents have been\n",
      "tested as second-line options in the post-docetaxel set-\n",
      "ting, in the frame of randomized phase III studies.\n",
      "The present systematic review aimed to analyze the pub-\n",
      "lished evidence on post-docetaxel therapy for patients\n",
      "affected by mCRPC, in order to evaluate the efficacy and\n",
      "safety of novel treatments, compared with active drugs or\n",
      "placebo. Meta-analysis was also performed to evaluateDOI:10.4081/aiua.2015.2.121\n",
      "to best of care at the time of study (mitoxantrone-pred-\n",
      "nisone). Agents targeting the androgen axis (enzalutamide,\n",
      "abiraterone, orteronel) signiﬁcantly prolonged rPFS, com-\n",
      "pared to placebo. Further investigation is warranted to eval-\n",
      "uate the beneﬁt of combination or sequential administration\n",
      "of these agents. Large-scale studies are also necessary to\n",
      "evaluate the impact of relevant toxic effects observed in a\n",
      "limited number of patients (e.g., enzalutamide-induced\n",
      "seizures, orteronel-induced pancreatitis, and others).\n",
      "KEYWORDS:Castration-resistant prostate cancer; Hormone\n",
      "therapy; chemotherapy.\n",
      "Submitted 15 March 2015; Accepted 31 March 2015Perletti_Stesura Seveso  02/07/15  11:19  Pagina 121\n",
      "Archivio Italiano di Urologia e Andrologia 2015; 87, 2G. Perletti, E. Monti, E. Marras, A. Cleves, V. Magri, A. Trinchieri, P.S Rennie\n",
      "122the effect of agents targeting the androgen axis on sur-\n",
      "vival, and to assess the adverse effects of treatment.\n",
      "MATERIALSANDMETHODS\n",
      "This review was prepared following the PRISMA check-\n",
      "list (5). MECIR criteria (http://editorial-unit.cochrane.\n",
      "org/mecir) were implemented whenever possible, within\n",
      "the word count limits established by the journal.\n",
      "Eligibility criteria\n",
      "We included phase III randomized controlled trials (RCT)\n",
      "that enrolled patients with mCRPC progressing during or\n",
      "after first-line docetaxel treatment. We included compar-\n",
      "isons of an experimental systemic intervention with place-\n",
      "bo or an active treatment, combined or not with a corti-\n",
      "costeroid. We excluded from the present review (i) studies\n",
      "including post-hoc evaluations of RCTs, (ii) studies based\n",
      "on bone-targeting interventions aimed at palliating pain or\n",
      "preventing skeletal complications (e.g., radioisotopes, bis-\n",
      "phosphonates, external beam radiation), (iii) studies\n",
      "including patients treated with protocols based on non\n",
      "taxane first-line agents, and (iv) studies investigating doc-\n",
      "etaxel-based therapies in the post-docetaxel setting (e.g.,\n",
      "intermittent or combination therapies).\n",
      "Outcomes\n",
      "The primary outcome was overall survival, calculated from\n",
      "the date of randomization to death. Secondary outcomes\n",
      "were radiographic progression-free survival (rPFS), calcu-\n",
      "lated between the date of randomization and the first date\n",
      "of radiographic progression, and adverse effects of grade 3\n",
      "or higher. \n",
      "Search strategy and study selection\n",
      "Published study reports and supplementary material were\n",
      "identified by searching PubMed, MEDLINE, EMBASE, The\n",
      "Cochrane Library, Web of Science, BIOSIS, LILACS, other\n",
      "databases and trial registry platforms. Search strategies are\n",
      "available as on-line supplementary data to the present\n",
      "review. Database searches covered the period between\n",
      "January 2004 (the year docetaxel was first approved as\n",
      "first-line therapy for CRPC) and January 2015.\n",
      "Quality assessment\n",
      "The risk of bias (ROB) of included studies was assessed\n",
      "by three reviewers using the Cochrane Collaboration’s\n",
      "tool (7). ROB was graded as high, low, or unclear.\n",
      "Significant bias can be generated depending on how data\n",
      "are managed to estimate time-to-event endpoints like\n",
      "rPFS, where the exact time of progression is not known in\n",
      "most cases. In some studies, the date of death is imputed\n",
      "as the progression event. In others, rPFS is censored at the\n",
      "date of the last visit at which the patient is assessed to be\n",
      "progression-free. Studies adopting the latter approach\n",
      "were considered to be at low ROB (8), whereas for trials\n",
      "adopting other imputation strategies (i.e., date of first visit\n",
      "post-progression or death used to estimate progression)\n",
      "the risk of attrition bias was rated as high. Studies includ-\n",
      "ing patients who discontinued anti-androgen therapy on-\n",
      "trial were considered at high ROB (study design bias), due\n",
      "to the confounding effect of androgen withdrawalresponses. The quality of the evidence resulting from\n",
      "pooled data analysis was evaluated using the GRADE\n",
      "framework, and reported in a summary of findings table\n",
      "(Table 3) (9).\n",
      "Data collection and statistical analysis\n",
      "Data extraction was performed by three reviewers. For\n",
      "time-to-event data, hazard ratios (HR) were extracted\n",
      "from study reports. To analyze grade ≥ 3 adverse effects\n",
      "at specific study time points, the number of intent-to-\n",
      "treat patients was extracted, and risk ratios (RR) were\n",
      "calculated. Analyses included the calculation of 95%\n",
      "confidence intervals (CI). We analyzed only available\n",
      "information (available case analysis), without employing\n",
      "bias-prone data imputation strategies for missing data.\n",
      "For analysis of pooled data we used a fixed-effects\n",
      "model. Heterogeneity was assessed by calculating the I²\n",
      "value. Given the small number of studies (two per meta-\n",
      "analysis) we did not employ formal methods to explore\n",
      "heterogeneity or to assess for publication bias. Data\n",
      "analysis was performed using the RevMan 5.3 software.\n",
      "RESULTS\n",
      "Results of the search and study inclusion\n",
      "A flow-chart of the search and screening process is shown\n",
      "in Figure 1. A total of 6518 publications were identified\n",
      "using our search strategy. From 36 potentially relevant\n",
      "articles selected by two independent reviewers on the\n",
      "Figure 1. Study selection process for the present review.\n",
      "We retrieved total 6518 records from the following\n",
      "sources: MEDLINE (1483 records retrieved); EMBASE\n",
      "(1892 records retrieved); PubMed (314 records retrieved);\n",
      "The Cochrane Library (234 records retrieved); Web of\n",
      "Science (1313 records retrieved); BIOSIS (905 records\n",
      "retrieved); LILACS (15 records retrieved); WHO\n",
      "International Clinical Trials Registry Search Portal (362\n",
      "records retrieved).\n",
      "Perletti_Stesura Seveso  02/07/15  11:19  Pagina 122\n",
      "123 Archivio Italiano di Urologia e Andrologia 2015; 87, 2Second-line agents for castration-resistant prostate cancer\n",
      "basis of title and abstract content, 10 articles met the\n",
      "inclusion criteria for the present review. \n",
      "These articles report the results of five clinical trials:\n",
      "AFFIRM (enzalutamide versus placebo) (10), CA184-043\n",
      "(ipilimumab versus placebo) (11), COU-AA-301 (abi-\n",
      "raterone acetate/ predni sone versus placebo/prednisone)\n",
      "(12-15), TAK-700 (orteronel/prednisone versus placebo/\n",
      "prednisone) (16), TROPIC (cabazitaxel/prednisone versus\n",
      "mitoxantrone/prednisone) (17-19). Table 1 summarizes\n",
      "the characteristics of the included studies, the experimen-\n",
      "tal interventions and key baseline patient characteristics.\n",
      "Risk of bias in included studies \n",
      "Table 2 and Figure 2 summarize the ROB evaluations for\n",
      "the included studies. High ROB was assessed in few\n",
      "cases. The TROPIC trial was an open-label study, having\n",
      "high risk of selection and performance/detection bias.\n",
      "The AFFIRM trial was considered as presenting high risk of\n",
      "attrition bias, since a marked imbalance was found\n",
      "between censored PFS data in the placebo (62%) and the\n",
      "enzalutamide (38%) arms. In the CA184-043 and COU-\n",
      "AA-301 studies, a high number of censored survival data\n",
      "suggests high risk of attrition bias. In the CA184-043 trial,Table 1. Characteristics of included studies and baseline participant data.\n",
      "ECOG = Eastern Cooperative Oncology Group Performance Status; BPI = Brief Pain Inventory Score; ND = Not Determined.\n",
      "Figure 2. Risk of bias summary. Green circles represent low\n",
      "risk of bias; red circles represent high risk of bias; yellow\n",
      "circles represent unknown risk of bias.Perletti_Stesura Seveso  02/07/15  11:19  Pagina 123\n",
      "Archivio Italiano di Urologia e Andrologia 2015; 87, 2G. Perletti, E. Monti, E. Marras, A. Cleves, V. Magri, A. Trinchieri, P.S Rennie\n",
      "124palliative radiotherapy was allowed for any bone lesion on-\n",
      "study, and a variable number of lesions was irradiated in\n",
      "each patient to stimulate an immune response, using doses\n",
      "equivalent to external beam palliative radiotherapy. \n",
      "Thus, different numbers of patients in each treatment arm\n",
      "may have received different doses of radiation, and the riskof bias due to inter-arm unbalanced radiation treatment\n",
      "may be high.\n",
      "Effects of interventions \n",
      "The ten articles included in the present review reported\n",
      "the data of five clinical trials. A total of 5047 patients\n",
      "Table 2. Risk of bias (ROB) of the included studies.Perletti_Stesura Seveso  02/07/15  11:19  Pagina 124\n",
      "were randomized to experimental (n = 3108) or control\n",
      "interventions (placebo/active drug; n = 1939). Overall\n",
      "and progression-free survival data are presented. Due to\n",
      "limited space, severe (grade ≥3) adverse effect data are\n",
      "presented as on-line supplementary material.\n",
      "Enzalutamide versus placebo (AFFIRM study)\n",
      "At interim analysis (520 death events), median overall\n",
      "survival was found to be prolonged in the enzalutamide\n",
      "arm, compared to placebo (18.4 vs. 13.6 months,\n",
      "respectively). The hazard ratio for death was 0.63 (95%\n",
      "CI 0.53 to 0.75, P<0.00001, Figure 3) (10).\n",
      "Radiographic progression-free survival was significantly\n",
      "prolonged in the enzalutamide arm, compared to place-\n",
      "bo (11 vs. 5.6 months, HR: 0.40, 95% CI 0.35 to 0.46;\n",
      "P<0.0001, Figure 3).\n",
      "Ipilimumab versus placebo (CA184-043 study)\n",
      "The median overall survival in the ipilimumab arm was\n",
      "11.2 months, compared to 10.0 months in the placebo\n",
      "arm, resulting in a hazard ratio for death of 0.85 (95%\n",
      "CI 0.72 to 1.0; P = 0.053 [P = 0.06 in our analysis],\n",
      "Figure 3 (11).\n",
      "A composite PFS endpoint was adopted for the present\n",
      "study, and rPFS data were not available.Abiraterone acetate versus placebo (COU-AA-301 study)\n",
      "Administration of abiraterone acetate plus prednisone\n",
      "resulted in significantly prolonged overall survival com-\n",
      "pared to placebo plus prednisone. \n",
      "The median overall survival in the abiraterone arm was\n",
      "14.8 months, compared to 10.9 months in the placebo\n",
      "arm, resulting in a significant hazard ratio of 0.65 (95%\n",
      "CI 0.54 to 0.78; P<0.00001, Figure 3) (12-15).\n",
      "Radiographic progression-free survival was significantly\n",
      "prolonged in the abiraterone arm, compared to placebo\n",
      "(5.6 vs. 3.6 months; HR for rPFS or death: 0.66, 95% CI\n",
      "0.58 to 0.75; P < 0.00001, Figure 3).\n",
      "Orteronel versus placebo (TAK-700 study)\n",
      "The median overall survival in the orteronel arm was\n",
      "17.0 months, compared to 15.2 months in the placebo\n",
      "arm, resulting in a hazard ratio of 0.89 (95% CI 0.74 to\n",
      "1.06; P = 0.19, Figure 3). \n",
      "The study was unblinded after crossing a futility bound-\n",
      "ary for overall survival (16).\n",
      "Radiographic progression-free survival was significantly\n",
      "prolonged in the orteronel arm, compared to placebo\n",
      "(8.3 vs. 5.7 months; HR: 0.76, 95% CI 0.65 to 0.88;\n",
      "P=0.0004, Figure 3).\n",
      "125 Archivio Italiano di Urologia e Andrologia 2015; 87, 2Second-line agents for castration-resistant prostate cancer\n",
      "Table 3. Summary of ﬁndings table for the pooled analysis of COU-AA-30112 and TAK-70016 studies.\n",
      "CI: Conﬁdence interval; HR: Hazard Ratio; RR: Risk Ratio; ND: Not Determined.\n",
      "1 Downgraded for considerable heterogeneity (-1). \n",
      "2 Downgraded for high risk of attrition bias (-1) and moderate heterogeneity (-1).\n",
      "The corresponding risk (and its 95% conﬁdence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention\n",
      "(and its 95% CI).\n",
      "GRADE Working Group grades of evidence.\n",
      "High quality: Further research is very unlikely to change our conﬁdence in the estimate of effect.\n",
      "Moderate quality: Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate.\n",
      "Low quality: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change the estimate.\n",
      "Very low quality: We are very uncertain about the estimate.\n",
      "Perletti_Stesura Seveso  02/07/15  11:19  Pagina 125\n",
      "Archivio Italiano di Urologia e Andrologia 2015; 87, 2G. Perletti, E. Monti, E. Marras, A. Cleves, V. Magri, A. Trinchieri, P.S Rennie\n",
      "126Cabazitaxel versus mitoxantrone (TROPIC study)\n",
      "Treatment with cabazitaxel plus prednisone resulted in\n",
      "significantly prolonged overall survival compared to\n",
      "mitoxantrone plus prednisone. The median overall sur-\n",
      "vival in the cabazitaxel arm was 15.1 months, compared\n",
      "to 12.7 months in the mitoxantrone arm (HR: 0.70, 95%\n",
      "CI 0.59 to 0.83, p < 0.0001, Figure 3) (17). \n",
      "A composite PFS endpoint was adopted for the present\n",
      "study. Radiographic progression-free survival data were\n",
      "not available.Intervention active on the androgen axis versus \n",
      "placebo (pooled analysis)\n",
      "We merged two studies (COU-AA-301 and TAK-700)\n",
      "(12, 16) including in total 2294 participants (1531 in the\n",
      "active intervention arm, 763 in the placebo arm) treated\n",
      "with the androgen synthesis inhibitors (ASI) abiraterone\n",
      "and orteronel, showing equivalent mechanisms of action\n",
      "(selective inhibition 17α-hydroxylase and 17,20-lyase\n",
      "activities of CYP17A1). Both studies used placebo plus\n",
      "prednisone as a comparator. Analysis of overall survivalFigure 3. Summary of overall survival and radiographic progression-free survival of the included studies. Since disease\n",
      "progression was a composite endpoint in the CA184-043 and TROPIC studies, radiographic progression-free survival data\n",
      "were not available. The number of randomized subjects, hazard ratios for death or progression, the 95% conﬁdence\n",
      "intervals for hazard ratios, the Z value and the signiﬁcance of the single comparisons are presented.\n",
      "Perletti_Stesura Seveso  02/07/15  11:19  Pagina 126\n",
      "resulted in a significantly lower hazard ratio for death of\n",
      "ASI compared to placebo (HR: 0.76, 95% CI 0.67 to 0.87;\n",
      "P < 0.0001, Figure 4). The quality of the evidence was\n",
      "moderate (Table 3). Considerable heterogeneity emerged\n",
      "from this analysis (I2=82%, Chi2=5.54, P=0.02).\n",
      "Pooled analysis resulted in a significantly decreased hazard\n",
      "ratio for radiographic progression of the active interven-\n",
      "tions versus placebo (HR: 0.7, 95% CI 0.63 to 0.77;\n",
      "P<0.00001, Figure 4). The quality of the evidence was\n",
      "low (Table 3). Moderate heterogeneity was detected for\n",
      "this pooled comparison (I2= 48%, Chi2= 1.93, P=0.17).\n",
      "The number of pooled studies was not sufficient for an\n",
      "investigation of the causes of heterogeneity. It is conceiv-\n",
      "able that the different methods used for censoring missing\n",
      "data between studies may have contributed to the genera-\n",
      "tion of heterogeneity. ASI induced significant increases in\n",
      "adverse effects linked to elevated mineralocorticoid secre-\n",
      "tion. The risk-ratio for hypokalemia was significantly\n",
      "enhanced in the ASI arm versus placebo (RR: 5.75, 95%\n",
      "CI 2.08 to 15.90; P=0.0008). The risk ratio for hyper-\n",
      "tension, not significantly higher in each separate study,\n",
      "was also significantly increased in our analysis (RR: 2.29,\n",
      "95% CI 1.02 to 5.17; P=0.05). Pain in the extremities was\n",
      "less frequently detected in the ASI arm, compared to\n",
      "placebo (RR 0.55, 95% CI 0.34 to 0.89; P=0.02). Pooled\n",
      "comparisons of AEs did not show heterogeneity (I2= 0%\n",
      "in all cases). A complete list of grade ≥3 adverse effects is\n",
      "presented as supplementary material.\n",
      "DISCUSSION\n",
      "Until recently, docetaxel, administered at the standard\n",
      "dose of 75 mg/m2every three weeks, was the only ther-\n",
      "apeutic option with proven life-prolonging efficacy for\n",
      "the management of mCRPC. In the last few years new\n",
      "agents have been approved worldwide for second-line\n",
      "treatment of patients affected by docetaxel-refractorymCRPC. The present review analyzed clinical data\n",
      "extracted from RCTs focusing on treatment of mCRPC\n",
      "patients in the post-docetaxel setting.\n",
      "Five studies were considered, representing a total popula-\n",
      "tion of 5047 patients. Different baseline characteristics\n",
      "between studies (e.g., the prevalence of highly-prognostic\n",
      "visceral metastases or severe pain at enrollment) likely\n",
      "explain the inter-study variability of overall survival, espe-\n",
      "cially as assessed in the control arms of each trial (Table 1).\n",
      "In three studies, treatment with the experimental inter-\n",
      "ventions could significantly prolong the median overall\n",
      "survival of patients. Compared to control cohorts, the\n",
      "survival advantages were 4.8 months for the androgen\n",
      "receptor antagonist enzalutamide, 4.6 months for the\n",
      "androgen synthesis inhibitor abiraterone and 2.4 months\n",
      "for the cytotoxic taxane cabazitaxel (10, 12, 17).\n",
      "Radiographic progression-free survival data were avail-\n",
      "able for the enzalutamide vs. placebo comparison (rPFS\n",
      "advantage: 5.4 months) (10), for the abiraterone vs.\n",
      "placebo comparison (rPFS advantage: 2 months) (12),\n",
      "and for the orteronel vs. placebo comparison (rPFS\n",
      "advantage: 2.6 months) (16). In all cases hazard ratios\n",
      "were statistically significant, demonstrating the efficacy\n",
      "of these agents in delaying progression of the disease.\n",
      "All patients enrolled in the included studies had prostate\n",
      "cancer progressing after androgen-deprivation therapy.\n",
      "Three studies involved drugs acting on the androgen\n",
      "axis: abiraterone acetate, orteronel and enzalutamide.\n",
      "Pooled analysis of studies involving abiraterone acetate\n",
      "plus prednisone and orteronel plus prednisone con-\n",
      "firmed that androgen synthesis inhibitors can signifi-\n",
      "cantly increase both overall survival and rPFS, compared\n",
      "to placebo-prednisone (Figure 4). Meta-analysis of over-\n",
      "all survival contained data from a study (TAK-700) that\n",
      "was prematurely unblinded, due to demonstrated futili-\n",
      "ty, and results must be considered conservatively.\n",
      "Nevertheless, the significant survival benefit resulting\n",
      "127 Archivio Italiano di Urologia e Andrologia 2015; 87, 2Second-line agents for castration-resistant prostate cancer\n",
      "Figure 4. Pooled analysis of overall survival and radiographic progression-free survival of the COU-AA-301 and TAK-700\n",
      "studies, comparing the effect of inhibitors of the 17α-hydroxylase and 17,20-lyase activities of the enzyme CYP17A1,\n",
      "involved in the biosynthesis of testosterone, combined with prednisone, and placebo-prednisone. The number of\n",
      "randomized subjects, hazard ratios for death or progression, the 95% conﬁdence intervals for hazard ratios, the Z value\n",
      "for the overall effect, the signiﬁcance of the pooled comparison and heterogeneity data (Chi2, I2), are presented. \n",
      "Data to left of the black line of forest plots represent greater reduction of the hazard ratios for death or progression in\n",
      "patients treated with androgen synthesis inhibitors. Diamonds represent pooled overall effect sizes for each outcome,\n",
      "which extend to the limits of the 95% conﬁdence intervals of hazard ratios.\n",
      "Perletti_Stesura Seveso  02/07/15  11:19  Pagina 127\n",
      "Archivio Italiano di Urologia e Andrologia 2015; 87, 2G. Perletti, E. Monti, E. Marras, A. Cleves, V. Magri, A. Trinchieri, P.S Rennie\n",
      "128from this analysis substantiates the evidence that mCRPC\n",
      "is not refractory to interventions aimed at further sup-\n",
      "pressing the androgen axis in patients subjected to surgi-\n",
      "cal or pharmacological castration, and shows that in\n",
      "these patients the androgen receptor-mediated signaling\n",
      "may remain functional and may actively modulate dis-\n",
      "ease progression. \n",
      "In addition, meta-analysis of the COU-AA-301 and\n",
      "TAK700 studies evidenced the appearance of severe\n",
      "adverse effects that can be attributed to mineralocorti-\n",
      "coid excess, like hypertension and hypokalemia.\n",
      "All experimental agents showed diverse severe adverse\n",
      "effects, which were lethal in some cases. Notably, cabaz-\n",
      "itaxel plus prednisone induced neutropenia of grade ≥ 3\n",
      "in 82% of cases, and grade ≥ 3 febrile neutropenia, lethal\n",
      "in 5% of cases. This prompted the FDA to recommend\n",
      "prophylactic neutrophil growth factor support in suscep-\n",
      "tible patients (20).\n",
      "Rare adverse effects worthy of further consideration were\n",
      "also observed in some of the included studies. For exam-\n",
      "ple, during the phase I-II investigation of enzalutamide,\n",
      "2% of patients treated with doses ≥ 360 mg/day had\n",
      "seizures (21). Although in the AFFIRM study the risk-\n",
      "ratio for seizure was not significant (10), five (or seven,\n",
      "according to the FDA medical review of the study) enza-\n",
      "lutamide-treated patients had seizures, whereas in the\n",
      "placebo arm no seizure events were reported.\n",
      "Seven patients treated with orteronel were diagnosed\n",
      "with pancreatitis and increased pancreatic enzyme levels.\n",
      "Hence, pancreas toxicity deserves further investigation\n",
      "and particular clinical attention.\n",
      "In conclusion, several new agents have shown to be effec-\n",
      "tive in prolonging survival in men with metastatic castra-\n",
      "tion-resistant prostate cancer in the post-docetaxel setting.\n",
      "It may be hypothesized that survival may be further pro-\n",
      "longed by combining these agents or by administering\n",
      "them sequentially. Randomized studies are warranted to\n",
      "demonstrate this hypothesis, but also to exclude recipro-\n",
      "cal detrimental effects of these agents (22-26).\n",
      "ACKNOWLEDGMENTS\n",
      "We acknowledge the contributions of Dr. Philipp Dahm\n",
      "and Dr. Molly Neuberger, of the Cochrane Collaboration.\n",
      "REFERENCES\n",
      "1. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of\n",
      "prostate cancer: an autopsy study of 1,589 patients. Hum Pathol.\n",
      "2000; 31:578.\n",
      "2-Droz JP, Flechon A, Terret C. Prostate cancer: management of\n",
      "advanced disease. Ann Oncol. 2002; 13 Suppl4: 89.\n",
      "3. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate\n",
      "cancer. Part II: Treatment of advanced, relapsing, and castration-\n",
      "resistant prostate cancer. Eur Urol. 2011; 59:572.\n",
      "4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone\n",
      "or mitoxantrone plus prednisone for advanced prostate cancer. New\n",
      "Engl J Med. 2004; 351:1502.\n",
      "5. Mathew P, Dipaola R. Taxane refractory prostate cancer. J Urol.\n",
      "2007; 178:S36.6. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for\n",
      "systematic reviews and meta-analyses: the PRISMA statement. Ann\n",
      "Intern Med. 2009; 151:264.\n",
      "7.Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane\n",
      "Collaboration's tool for assessing risk of bias in randomised trials.\n",
      "BMJ. 2011; 343:d5928.\n",
      "8. Niimi M, Yamamoto S, Fukuda H, et al. The Influence of handling\n",
      "censored data on estimating progression-free survival in cancer clin-\n",
      "ical trials (JCOG9913-A). Japan J Clin Oncol. 2002; 32:19.\n",
      "9. Guyatt GH, Oxman AD, Kunz R, et al. What is \"quality of evi-\n",
      "dence\" and why is it important to clinicians? BMJ 2008; 336:995.\n",
      "10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enza-\n",
      "lutamide in prostate cancer after chemotherapy. New Engl J Med.\n",
      "2012; 367:1187.\n",
      "11. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus place-\n",
      "bo after radiotherapy in patients with metastatic castration-resistant\n",
      "prostate cancer that had progressed after docetaxel chemotherapy\n",
      "(CA184-043): a multicentre, randomised, double-blind, phase 3\n",
      "trial. Lancet oncol. 2014; 15:700.\n",
      "12. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and\n",
      "increased survival in metastatic prostate cancer. New Engl J Med.\n",
      "2011; 364:1995.\n",
      "13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treat-\n",
      "ment of metastatic castration-resistant prostate cancer: final overall\n",
      "survival analysis of the COU-AA-301 randomised, double-blind,\n",
      "placebo-controlled phase 3 study. Lancet Oncol. 2012; 13:983.\n",
      "14. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone\n",
      "acetate and prednisone compared with placebo and prednisone on pain\n",
      "control and skeletal-related events in patients with metastatic castra-\n",
      "tion-resistant prostate cancer: exploratory analysis of data from the\n",
      "COU-AA-301 randomised trial. Lancet Oncol. 2012; 13:1210.\n",
      "15. Sternberg CN, Molina A, North S, et al. Effect of abiraterone\n",
      "acetate on fatigue in patients with metastatic castration-resistant\n",
      "prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;\n",
      "24:1017.\n",
      "16. Fizazi K, Jones R, Oudard S, et al. Phase III, Randomized,\n",
      "Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700)\n",
      "Plus Prednisone With Placebo Plus Prednisone in Patients With\n",
      "Metastatic Castration-Resistant Prostate Cancer That Has\n",
      "Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. J\n",
      "Clin Oncol. 2015; pii: JCO.2014.56.5119 [Epub ahead of print].\n",
      "17. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus\n",
      "cabazitaxel or mitoxantrone for metastatic castration-resistant\n",
      "prostate cancer progressing after docetaxel treatment: a randomised\n",
      "open-label trial. Lancet 2010; 376:1147.\n",
      "18. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treat-\n",
      "ment of metastatic castration-resistant prostate cancer. Fut Oncol.\n",
      "2011; 7:497.\n",
      "19. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-\n",
      "year survival and palliation of tumour-related pain in men with\n",
      "metastatic castration-resistant prostate cancer treated in the TROP-\n",
      "IC trial. Ann Oncol. 2013; 24:2402.\n",
      "20. Cookson MS, Roth BJ, Dahm P, et al. Castration-Resistant\n",
      "Prostate Cancer: AUA Guideline. J Urol. 2013; 190:429.\n",
      "21. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of\n",
      "MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.\n",
      "Lancet 2010; 375:1437.\n",
      "22. Sartor O, Pal SK. Abiraterone and its place in the treatment of\n",
      "metastatic CRPC. Nature Rev Clin Oncol. 2013; 10:6.Perletti_Stesura Seveso  02/07/15  11:19  Pagina 128\n",
      "23. Aggarwal R, Halabi S, Kelly WK, et al. The effect of prior andro-\n",
      "gen synthesis inhibition on outcomes of subsequent therapy with doc-\n",
      "etaxel in patients with metastatic castrate-resistant prostate cancer:\n",
      "results from a retrospective analysis of a randomized phase 3 clini-\n",
      "cal trial (CALGB 90401). Cancer 2013; 119:3636.\n",
      "24. Noonan KL, North S, Bitting RL, et al. Clinical activity of abi-\n",
      "raterone acetate in patients with metastatic castration-resistant\n",
      "prostate cancer progressing after enzalutamide. Ann Oncol. 2013;\n",
      "24:1802.25. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abi-\n",
      "raterone acetate against metastatic castration-resistant prostate\n",
      "cancer progressing after docetaxel and enzalutamide (MDV3100).\n",
      "Ann Oncol. 2013; 24:1807.\n",
      "26. Bianchini D, Lorente D, Rodriguez-Vida A, et al. Antitumour\n",
      "activity of enzalutamide (MDV3100) in patients with metastatic\n",
      "castration-resistant prostate cancer (CRPC) pre-treated with doc-\n",
      "etaxel and abiraterone. Eur J Cancer 2014; 50:78.\n",
      "129 Archivio Italiano di Urologia e Andrologia 2015; 87, 2Second-line agents for castration-resistant prostate cancer\n",
      "Correspondence\n",
      "Gianpaolo Perletti, PhD, M Clin Pharmacol (Corresponding Author)\n",
      "gianpaolo.perletti@uninsubria.it\n",
      "Elena Monti, PhD \n",
      "Emanuela Marras, PhD \n",
      "Biomedical Research Division, Dept. of Theoretical and Applied Sciences\n",
      "Università degli Studi dell’Insubria\n",
      "Via A. da Giussano, 10 - 21052 Busto Arsizio, Italy\n",
      "Anne Cleves, Msc\n",
      "Cancer Research Wales Library, Cardiff University Velindre Hospital\n",
      "Cardiff, UK\n",
      "Vittorio Magri, MD\n",
      "Urology Secondary Care Clinic, Istituti Clinici di Perfezionamento\n",
      "Milano, Italy\n",
      "Alberto Trinchieri, MD\n",
      "Urology Unit, A. Manzoni Hospital, Lecco, Italy\n",
      "Paul S Rennie, PhD, FCAHS\n",
      "Vancouver Prostate Centre, University of British Columbia\n",
      "Vancouver, CanadaPerletti_Stesura Seveso  02/07/15  11:19  Pagina 129\n"
     ]
    }
   ],
   "source": [
    "loader = PyPDFLoader(\n",
    "    \"/home/ubuntu/Multi-Agent-LLM-System-with-LangGraph-RAG-and-LangChain/filtered_dataset_csv_pdfs/10.4081_aiua.2015.2.121.pdf\"\n",
    ")\n",
    "pages = loader.load()\n",
    "print(len(pages))\n",
    "content = \"\\n\".join(page.page_content for page in pages)\n",
    "print(content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "nvembed",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
